Endothelial Dysfunction Associated With Drug-Eluting Stents. What, Where, When, and How?**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 51, Issue 22, 2008, Pages 2139-2140

  Muhlestein, Joseph B ^a  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BIOLIMUS A9; CYPHER; DRUG CARRIER; FIBRIC ACID DERIVATIVE; GLYCERYL TRINITRATE; NEBIVOLOL; NICOTINIC ACID; PACLITAXEL; RAPAMYCIN;

DRUG BINDING; DRUG ELUTING STENT; DRUG MECHANISM; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; HYPERSENSITIVITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THROMBOSIS;

ANIMALS; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MITOCHONDRIA, HEART; NADPH OXIDASE; NITRIC OXIDE; REACTIVE OXYGEN SPECIES; SIROLIMUS; SUPEROXIDES; VASOCONSTRICTION; VASODILATION;

EID: 44049092357     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.02.057     Document Type: Editorial

References (16)

1. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1519-1521
2. Lüscher T.F., Steffel J., Eberli F.R., et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
3. Togni M., Raber L., Cocchia R., et al. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol 120 (2007) 212-220
4. Hofma S., Van der Giessen W., Van Dalen B., et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 27 (2006) 166-170
5. Togni M., Windecker S., Cocchia R., et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46 (2005) 231-236
6. Fuke S., Maekawa K., Kawamoto K., et al. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J 71 (2007) 220-225
7. Jabs A., Göbel S., Wenzel P., et al. Sirolimus-induced vascular dysfunction: increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation. J Am Coll Cardiol 51 (2008) 2130-2138
8. Hamilos M.I., Ostojic M., Beleslin B., et al., NOBORI CORE Investigators. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 51 (2008) 2123-2129
9. Otsuka Y., Chronos N.A.F., Apkarian R.P., and Robinson K.A. Scanning electron microscopic analysis of defects in polymer coatings of three commercially available stents: comparison of BiodivYsio, Taxus and Cypher Stents. J Invasive Cardiol 19 (2007) 71-76
10. Schachinger V., Britten M.B., and Zeiher A. Impaired epicardial coronary vasoreactivity predicts for adverse cardiovascular events during long-term follow-up. Circulation 101 (2000) 1899-1906
11. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
12. Lagerqvist B., James S.K., Stenestrand U., et al., SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
13. Wassmann S., Laufs U., Bäumer A.T., et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37 (2001) 1450-1457
14. Vaccari C.S., Hammoud R.A., Nagamia S.H., et al. Revisiting niacin: reviewing the evidence. J Clin Lipidol 1 (2007) 248-255
15. Koh K.K., Han S.H., Quon M.J., Ahn J.Y., and Shin E.K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28 (2005) 1419-1424
16. Tzemos N., Lim P.O., and MacDonald T.M. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 104 (2001) 511-514